Research and Markets has announced the addition of the "Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline Insights, 2017" drug pipelines to their offering.

Secondary Progressive Multiple Sclerosis - Pipeline Insights, 2017 provides in depth insights on the pipeline drugs and their development activities around the Secondary Progressive Multiple Sclerosis.

The This report covers the product profiles in various stages of development including Discovery, Pre - clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.

This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Secondary Progressive Multiple Sclerosis.

This report also assesses the Secondary Progressive Multiple Sclerosis therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Key Topics Covered:

  1. Secondary Progressive Multiple Sclerosis Overview
  2. Secondary Progressive Multiple Sclerosis Disease Associated
  3. Secondary Progressive Multiple Sclerosis Pipeline Therapeutics
  4. Secondary Progressive Multiple Sclerosis Therapeutics under Development by Companies
  5. Secondary Progressive Multiple Sclerosis Filed and Phase III Products
  6. Secondary Progressive Multiple Sclerosis Phase II Products
  7. Secondary Progressive Multiple Sclerosis Phase I and IND Filed Products
  8. Secondary Progressive Multiple Sclerosis Discovery and Pre-Clinical Stage Products
  9. Drug Candidate Profiles
  10. Secondary Progressive Multiple Sclerosis - Therapeutics Assessment
  11. Secondary Progressive Multiple Sclerosis - Discontinued Products
  12. Secondary Progressive Multiple Sclerosis - Dormant Products
  13. Companies Involved in Therapeutics Development for Secondary Progressive Multiple Sclerosis
  14. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/s5sdls/secondary